Ethical considerations in choosing a model for population-based cystic fibrosis carrier screening

Medical Journal of Australia

Volumn 193, Issue 3, 2010, Pages 157-160

  Modra, Lucy J ^a   Massie, R John ^b   Delatycki, Martin B ^a,c  

^a AUSTIN HEALTH   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; GOVERNMENT; HEALTH CARE ACCESS; HETEROZYGOTE DETECTION; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; MODEL; PATIENT AUTONOMY; POPULATION RESEARCH; PREGNANCY; PRENATAL SCREENING; REFUSAL TO PARTICIPATE; REVIEW; DECISION MAKING; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; GENETICS; PRENATAL DIAGNOSIS; PROCEDURES; THEORETICAL MODEL;

CHOICE BEHAVIOR; CYSTIC FIBROSIS; ETHICS, MEDICAL; FEMALE; GENETIC COUNSELING; GENETIC TESTING; HETEROZYGOTE DETECTION; HUMANS; MODELS, THEORETICAL; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 77955730776     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2010.tb03836.x     Document Type: Review

References (36)

1. Massie J, Forbes R, Dusart D, et al. Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis. J Paediatr Child Health 2007; 43: 721-723.
2. Williamson R. Universal community carrier screening for cystic fibrosis? Nat Genet 1993; 3: 195-201.
3. McClaren BJ, Delatycki MB, Collins V, et al. "It is not in my world": an exploration of attitudes and influences associated with cystic fibrosis carrier screening. Eur J Hum Genet 2008; 16: 435-444.
4. Honnor M, Zubrick SR, Walpole I, et al. Population screening for cystic fibrosis in Western Australia: community response. Am J Med Genet 2000; 93: 198-204.
5. Wei S, Quigg MH, Monaghan KG. Is cystic fibrosis carrier screening cost effective? Community Genet 2007; 10: 103-109.
6. Rowley PT, Loader S, Kaplan R. Prenatal screening for cystic fibrosis carriers: an economic evaluation. Am J Hum Genet 1998; 63: 1160-1174.
7. Laws P, Hilder L. Australia's mothers and babies 2006. Sydney: Australian Institute of Health and Welfare National Perinatal Statistics Unit, 2008. (AIHW Cat. No. PER 46; Perinatal statistics series no. 22.) http://www.aihw.gov.au/ publications/index.cfm/title/10634 (accessed May 2010).
8. Hartley NE, Scotcher D, Harris H, et al. The uptake and acceptability to patients of cystic fibrosis carrier testing offered in pregnancy by the GP. J Med Genet 1997; 34: 459-464.
9. Rostant K, Steed L, O'Leary P. Survey of the knowledge, attitudes and experiences of Western Australian women in relation to prenatal screening and diagnostic procedures. Aust N Z J Obstet Gynaecol 2003; 43: 134-138.
10. Loader S, Caldwell P, Kozyra A. Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet 1996; 59: 234-247.
11. Santalahti P, Hemminki E, Latikka AM, Ryynänen M. Women's decision-making in prenatal screening. Soc Sci Med 1998; 46: 1067-1076.
12. Press N, Browner CH. Why women say yes to prenatal diagnosis. Soc Sci Med 1997; 45: 979-989.
13. Gekas J, Gondry J, Mazur S, et al. Informed consent to serum screening for Down syndrome: are women given adequate information? Prenat Diagn 1999; 19: 1-7.
14. Jaques AM, Sheffield LJ, Halliday JL. Informed choice in women attending private clinics to undergo first-trimester screening for Down syndrome. Prenat Diagn 2005; 25: 656-664.
15. Statham H, Green J. Serum screening for Down's syndrome: some women's experiences. BMJ 1993; 307: 174-176.
16. Jaques AM, Halliday JL, Bell RJ. Do women know that prenatal testing detects fetuses with Down syndrome? J Obstet Gynaecol 2004; 24: 647-651.
17. Smith DK, Shaw RW, Marteau TM. Informed consent to undergo serum screening for Down's syndrome: the gap between policy and practice. BMJ 1994; 309: 776.
18. Cheffins T, Chan A, Haan EA, et al. The impact of maternal serum screening on the birth prevalence of Down's syndrome and the use of amniocentesis and chorionic villus sampling in South Australia. BJOG 2000; 107: 1453-1459.
19. Tambor ES, Bernhardt BA, Chase GA, et al. Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet 1994; 55: 626-637.
20. Henneman L, Bramsen I, van der Ploeg HM, et al. Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners. J Med Genet 2001; 38: 695-703.
21. Harris H, Scotcher D, Hartley N. Cystic fibrosis carrier testing in early pregnancy by general practitioners. BMJ 1993; 306: 1580-1583.
22. Thornton JG, Hewison J, Lilford RJ, Vail A. A randomised trial of three methods of giving information about prenatal testing. BMJ 1995; 311: 1127-1130.
23. Clausen H, Brandt NJ, Schwartz M, Skovby F. Psychological and social impact of carrier screening for cystic fibrosis among pregnant woman - a pilot study. Clin Genet 1996; 49: 200-205. (Pubitemid 26237104)
24. Statham H, Green J. Psychosocial aspects of prenatal screening and diagosis. In: Marteau T, Drake H, editors. The troubled helix: social and psychological implications of the new human genetics. Cambridge: Cambridge University Press, 1996: 140-163.
25. Modra L. Prenatal genetic testing kits sold at your local pharmacy: promoting autonomy or promoting confusion? Bioethics 2006; 20: 254-263.
26. Barlow-Stewart K, Burnett L, Proos A, et al. A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. J Med Genet 2003; 40: e45.
27. Gason AA, Delatycki MB, Metcalfe SA, Aitken M. It's "back to school" for genetic screening. Eur J Hum Genet 2006; 14: 384-389.
28. Mitchell J, Scriver CR, Clow CL, Kaplan F. What young people think and do when the option for cystic fibrosis carrier testing is available. J Med Genet 1993; 30: 538-542.
29. Bekker H, Modell M, Denniss G, et al. Uptake of cystic fibrosis testing in primary care: supply push or demand pull? BMJ 1993; 306: 1584-1586.
30. Mitchell JJ, Capua A, Clow C, Scriver CR. Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet 1996; 59: 793-798.
31. Frumkin A, Zlotogora J. Genetic screening for reproductive purposes at school: is it a good strategy? Am J Med Genet A 2008; 146A: 264-269.
32. Ross LF. Heterozygote carrier testing in high schools abroad: what are the lessons for the US? J Law Med Ethics 2006; 34: 753-764.
33. Gason AA, Sheffield E, Bankier A, et al. Evaluation of a Tay-Sachs disease screening program. Clin Genet 2003; 63: 386-392.
34. Delatycki MB, Wolthuizen M, Collins V, et al. Implementation of ironXS: a study of the acceptability and feasibility of genetic screening for hereditary hemochromatosis in high schools. Clin Genet 2010; 77: 241-248.
35. Delatycki M, Allen KJ, Niselle AE, et al. Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis. Lancet 2005; 366: 314-316.
36. Marteau TM, Croyle RT. The new genetics. Psychological responses to genetic testing. BMJ 1998; 316: 693-696.